Vikram Purohit
Stock Analyst at Morgan Stanley
(1.75)
# 3,395
Out of 5,045 analysts
159
Total ratings
31.75%
Success rate
-8.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $31.19 | +9.01% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $65.24 | +21.09% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $4.31 | +36.82% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $5.54 | -9.67% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $202.20 | +23.64% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $93.55 | -30.52% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $134.18 | +41.60% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.33 | +108.09% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $28.50 | +8.77% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $104.02 | -84.62% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.38 | +370.59% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $25.02 | -60.03% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $8.16 | -26.43% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $12.90 | +225.71% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $61.97 | -33.84% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $17.12 | +133.71% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $3.08 | +322.08% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $20.68 | +83.75% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.56 | +73.01% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.59 | -31.46% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.95 | +1,028.15% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $14.62 | +36.80% | 2 | Aug 5, 2020 |
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $31.19
Upside: +9.01%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $65.24
Upside: +21.09%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $4.31
Upside: +36.82%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $5.54
Upside: -9.67%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $202.20
Upside: +23.64%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $93.55
Upside: -30.52%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $134.18
Upside: +41.60%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.33
Upside: +108.09%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $28.50
Upside: +8.77%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $104.02
Upside: -84.62%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $6.38
Upside: +370.59%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $25.02
Upside: -60.03%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $8.16
Upside: -26.43%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $12.90
Upside: +225.71%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $61.97
Upside: -33.84%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $17.12
Upside: +133.71%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $3.08
Upside: +322.08%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $20.68
Upside: +83.75%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.56
Upside: +73.01%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $14.59
Upside: -31.46%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.95
Upside: +1,028.15%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $14.62
Upside: +36.80%